15, 19 or 21, resulting in a chromosome number between 46/47 to 75, as measured by conventional karyotyping; and/or a DNA index between 1.05 to 1. 75 . In contrast to other odd-numbered chromosomes frequently involved in hyperdiplody, chromosome 13 is often deleted instead [20, 21] . Moreover, trisomy of chromosome 11, to which CCND1 is localized, has been shown to result in direct upregulation of CCND1 [22, 23] . While the underlying mechanism leading to the aforementioned dichotomy of MM remains to be elucidated, it is noteworthy that, clinically, hyperdiploid MM patients are associated with better prognosis and treatment outcomes than the non-hyperdiploid MM patients [24] [25] [26] . Based on fluorescence in situ hybridization (FISH) analysis, del (13) is detected in 20% to 50% of MGUS, and approximately 50% of MM. Notably, 90% of del (13) is characterized by monosomy 13, and interstitial deletion of 13q14 occurs in the remaining 10% of cases [20, 21] . Despite that del (13) was once believed to impart poor prognosis, recently, the 6 prognostic impact of del (13) has been shown to be mediated by its strong association with unfavorable risk factor of t(4;14) [29, 30] .
By interphase FISH analysis, del(17p), which is the locus for tumor suppressor protein TP53, is generally found in less than 10% of MM patients at diagnosis. However, presence of del(17p) at diagnosis is a powerful negative prognostic factor for MM [31, 32] . A recent study of MM patients uniformly receiving bortezomib-based induction therapy prior to autologous stem cell transplantation further confirmed that del(17p) is associated with an inferior event-free survival (median time: 14 vs. 36 months) and overall survival (4-year OS: 50% vs. 79%) as compared with those without del(17p). Therefore, the adverse impact of del (17p) appears not abolished by the use of targeted therapy [33] .
RAS mutations, predominantly K-and N-RAS at codon 12, 13 and 61, but not H-RAS, is present in more than half of MM at diagnosis but not in MGUS, suggesting that the RAS mutations is at least a marker of the transition from MGUS to MM [34-37].
Last but not least, the bone marrow microenvironment is very important in the pathogenesis of MM for homing of MM plasma cell to the bone marrow and secretion of growth-stimulating cytokines to the MM plasma cells. The homing of MM plasma cell is a chemotaxis mechanism mediated by the bone marrow stromal cells secreted chemokine (C-X-C motif) ligand 12 or stromal cell-derived factor 1, which binds to its specific receptor, chemokine (C-X-C motif) receptor 4, expressed on the MM plasma cell. Moreover In MM, by genome-wide or gene-specific approaches, aberrant DNA methylation has been found to mediate the loss of a number of protein-coding tumor suppressor genes regulating cell cycle progression, cell signaling or apoptosis, including cyclin-dependent kinase inhibitor 2A (CDKN2A), cyclin-dependent kinase inhibitor 2B (CDKN2B), death-associated protein kinase, secreted frizzled-related protein 2 and suppressor of cytokine signaling 1 (SOCS1), etc [54,55].
DNA methylation

DNA methylation and cancer
Methods of DNA methylation analysis
Over the years, techniques of DNA methylation analysis have evolved from qualitative to quantitative in fashion, and from locus-specific to genome-wide in scale [56] [57] [58] (Table 1) .
Bisulfite conversion, which chemically deaminates or modifies unmethylated cytosine to In breast and cervical cancers, CDKN2A and SOCS1 are important tumor suppressor genes inactivated by DNA hypermethylation. [103, 104] . On the other hand, miR-24 and miR-155 are oncogenic miRNAs over-expressed in breast and cervical cancers [105, 106] .
Furthermore, miR-24 and miR-155 have been shown to target the 3'UTR of, and hence repress CDKN2A and SOCS1 respectively. [106, 107] . Therefore, in addition to gene hypermethylation, tumor suppressor genes can be translationally repressed by oncogenic miRNAs, suggesting that the Knudson's hypothesis can potentially be fulfilled by a complex co-operation of gene alterations with one allele inactivated by gene deletion, mutation or hypermethylation, and the other allele by miRNA targeting.
Thus, these data suggested that miRNAs play multifaceted role in carcinogenesis. Later part of this article focuses on the role of DNA methylation of tumor suppressor miRNAs in
MM.
Dysregulation of miRNAs in MM
Dysregulation of miRNAs has been implicated in MM [108, 109] . In brief, by miRNA expression profiling using hybridization or Taqman low-density array, miRNAs were found aberrantly expressed in MM cells as compared with their healthy counterparts [110] [111] [112] [113] [114] [115] [116] .
Moreover, miRNA signatures were found associated with distinct genetic subtypes, such as t(4;14), t(11;14) and t(14;16), and different clinical stages of MM [110, 112, [114] [115] [116] [117] .
Furthermore, of these dysregulated miRNAs, some were found to be involved in the regulation of cell cycle, proliferation and apoptosis. For examples, miR-21 and miR-17-92 were identified as oncogenic miRNAs, leading to enhanced survival and reduced apoptosis of MM [110, 118] . In particular, upregulation of miR-21, a downstream target of activator of transcription 3 (STAT3), was found to potentiate the proliferative IL6-mediated signal transducer and STAT3 signaling in MM. In contrast, miR-15a and miR-16-1 were found to be tumor suppressor miRNAs, resulting in increase of apoptosis and suppression of NFκB pathway in MM cells [111, 119] . Moreover, these studies showed that some known tumor suppressor miRNAs, such as let-7, miR-29 and miR-193, are downregulated in MM.
Downregulation of miRNA expression in cancers may be mediated by various mechanisms, ranging from epigenetic inactivation, gene mutation or copy number loss to defective miRNA biogenesis or post-transcriptional processing [120] . Of these, DNA methylation is associated with repression of miRNAs possessing promoter-associated CpG islands [121] . Furthermore, the expressions and functions of these tumor suppressor miRNAs can be reversed and restored by DNA hypomethylation treatment [122] . Therefore a better understanding of epigenetic inactivation of tumor suppressor miRNA genes is essential for the biology and treatment in human cancers including MM. Recently, the following studies described the role of DNA methylation of tumor suppressor miRNA genes, With the presence of promoter-associated CpG island at each of the miR-34a (1p36) and miR-34b/c (11q23) promoters, frequent DNA hypermethylation of the miR-34s gene, leading to silencing of the miR-34s, and hence upregulation of the miR-34s target genes has been found in a wide range of solid cancers, including bladder, breast, colon, lung, melanoma, neuroblastoma, prostate, and ovarian cancer, etc [126, 127, 129, 130, [140] [141] [142] [143] .
In hematological cancers, Chim et al. studied the methylation status of the miR-34a in a broad spectrum of primary samples, consist of AML, chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), MM, non-Hodgkin's lymphoma (NHL) and Philadelphia chromosome negative (Ph-ve) myeloproliferative diseases (MDS) [144, 145] . Both of these studies showed that the promoter-associated CpG island of the miR-34a was unmethylated in normal controls but aberrantly methylated in 50% of the hematological cancer cell lines, including human myeloma cell lines (HMCLs). Treatment with 5-aza-2'-deoxycytidine led to demethylation of the miR-34a promoter and consequent re-expression of the pri-miR-34a transcript in cells homozygously methylated for the miR-34a. Among primary samples at diagnosis, the miR-34a promoter was preferentially methylated in 18.8% NHL (p=0.018), 5.5% MM, 4.0% CLL and 2.2% MDS and none of ALL, AML and CML. Furthermore, in MM, with paired primary samples of at diagnosis and at relapse/progression, it was also shown that methylation of the miR-34a promoter remained infrequent even at the time of disease relapse/progression. Therefore, in contrast to the frequent methylation of miR-34a in epithelial cancers [142, 146] , methylation of the miR-34a promoter appears unimportant in MM pathogenesis and progression.
miR-34b/c
In contrast to miR-34a, methylation of the miR-34b/c was implicated in the progression of MM [147] . In a recent study, the promoter-associated CpG island of the miR-34b/c was shown to be unmethylated in normal controls but aberrantly methylated in 75% of the 
miR-194-2-192
In addition to the miR-34s, which mediates TP53-associated tumor suppression, Figure 3 
